Longer Travel Time to Prostate Cancer Treatment Linked to Lower Mortality—Is Centralization the Explanation?
Highlight
– In a retrospective cohort of 159,943 US men with prostate cancer (2000–2015), estimated travel time to the treating facility ≥30 minutes was associated with lower adjusted risks of all-cause (aHR 0.91, 95% CI 0.89–0.93) and prostate cancer–specific mortality (aHR 0.90, 95% CI 0.86–0.95).
– The authors suggest this counterintuitive finding may reflect higher-quality or more specialized care concentrated at centers that draw patients from greater distances.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.